BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Investors buying this biotech stock now will get its pipeline essentially for free.

Moderna has nearly tripled in a single month without a single new trial result or analyst upgrade to explain Thursday's ...

BioNTech SE (NASDAQ:BNTX) is ending a mid-stage study of its personalized mRNA cancer vaccine, autogene cevumeran, after an independent monitoring committee concluded that continuing the trial was ...

Pfizer Canada ULC and BioNTech SE today announced that Health Canada has authorized the XFG variant-adapted COMIRNATY® for active immunization of individuals aged 6 months and older against COVID-19.

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating ...

By Bhanvi Satija and Sriparna Roy Aug 28 (Reuters) - BioNTech SE said it will end a mid-stage study of its experimental mRNA cancer vaccine after an independent committee found the treatment was ...

Over the past five years, BioNTech has lost 70% of its value. Could BioNTech bounce back soon, or is the company more likely to continue sinking over the next few years? Let's find out whether it's ...

BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, dashing hopes that had been raised by a rival drugmaker’s recent success in the field.

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...